Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
- Clin. Cancer Res., JANUARY 28 2022 | https://doi.org/10.1158/1078-0432.CCR-21-3646